Volume | 1,135,843 |
|
|||||
News | - | ||||||
Day High | 66.25 | Low High |
|||||
Day Low | 62.00 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
CONMED Corporation | CNMD | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
62.28 | 62.00 | 66.25 | 65.78 | 61.90 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
16,195 | 1,135,843 | $ 64.70 | $ 73,486,524 | - | 61.05 - 138.47 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:10:00 | 159,782 | $ 65.78 | USD |
CONMED (CNMD) Options Flow Summary
CONMED Corporation Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
3.12B | 30.78M | - | 1.24B | 64.46M | 2.09 | 48.43 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
CONMED News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CNMD Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 71.15 | 73.26 | 61.05 | 66.49 | 1,034,517 | -5.37 | -7.55% |
1 Month | 80.08 | 80.65 | 61.05 | 71.71 | 600,762 | -14.30 | -17.86% |
3 Months | 83.92 | 88.595 | 61.05 | 77.76 | 559,795 | -18.14 | -21.62% |
6 Months | 94.66 | 117.27 | 61.05 | 89.45 | 506,869 | -28.88 | -30.51% |
1 Year | 114.57 | 138.47 | 61.05 | 100.93 | 436,835 | -48.79 | -42.59% |
3 Years | 134.11 | 159.11 | 61.05 | 107.38 | 364,002 | -68.33 | -50.95% |
5 Years | 100.14 | 159.11 | 37.66 | 101.72 | 355,626 | -34.36 | -34.31% |
CONMED Description
Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgery. The firm currently reports through two reporting units, orthopedic surgery (52% of 2018 sales) and general surgery (48%). From a geographic perspective the firm is U.S. centric, with domestic sales accounting for 52% of revenue, EMEA accounting for 19%, APAC at 17%, and the non-U.S. Americas region driving the remaining 12%. |